Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial
Brilinta monotherapy reduced bleeding complications with no increased riskof ischaemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients undergoing complex percutaneous coronary interventionResults from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients. One subgroup analysis (TWILIGHT-DM) included